Phage therapy targeting Escherichia coli - a story with no end?

Simple item page
dc.contributor.authorBolocan, Andrei Sorin
dc.contributor.authorCallanan, Julie
dc.contributor.authorForde, Amanda
dc.contributor.authorRoss, R. Paul
dc.contributor.authorHill, Colin
dc.contributor.funderScience Foundation Irelanden
dc.contributor.funderJanssen Biotechen
dc.date.accessioned2017-08-01T11:29:26Z
dc.date.available2017-08-01T11:29:26Z
dc.date.issued2016-11-09
dc.date.updated2017-08-01T09:20:55Z
dc.description.abstractBacteriophages (phages) or bacterial viruses have long been proposed as an alternative therapy against antibiotic-resistant bacteria such as Escherichia coli. Even though poorly documented in the scientific literature, a long clinical history of phage therapy in countries such as Russia and Georgia suggests potential value in the use of phages as antibacterial agents. Escherichia coli is responsible for a wide range of diseases, intestinal (diarrhoea) and extraintestinal (UTI, septicaemia, pneumoniae, meningitis), making it an ideal target for phage therapy. This review discusses the latest research focusing on the potential of phage therapy to tackle E. coli-related illnesses. No intact phages are approved in EU or USA for human therapeutic use, but many successful in vitro and in vivo studies have been reported. However, additional research focused on in vivo multispecies models and human trials are required if phage therapy targeting E. coli pathotypes can be a story with happy end.en
dc.description.statusPeer revieweden
dc.description.versionAccepted Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationBolocan, A. S., Callanan, J., Forde, A., Ross, R. P. and Hill, C. (2016) 'Phage therapy targeting Escherichia coli - a story with no end?', Fems Microbiology Letters, 363(22), fnw256 (5pp). doi:10.1093/femsle/fnw256en
dc.identifier.doi10.1093/femsle/fnw256
dc.identifier.endpage5en
dc.identifier.issn0378-1097
dc.identifier.issued22en
dc.identifier.journaltitleFems Microbiology Lettersen
dc.identifier.startpage1en
dc.identifier.urihttps://hdl.handle.net/10468/4414
dc.identifier.volume363en
dc.language.isoenen
dc.publisherOxford University Pressen
dc.relation.projectScience Foundation Ireland (SFI/12/RC/2273; SFI/14/SP); Janssen Biotech (Research Grant)en
dc.rights© 2016, FEMS. All rights reserved. This is a pre-copyedited, author-produced version of an article accepted for publication in FEMS Microbiology Letters following peer review. The version of record: Bolocan, A. S., Callanan, J., Forde, A., Ross, P. and Hill, C. (2016) 'Phage therapy targeting Escherichia coli - a story with no end?', Fems Microbiology Letters, 363(22), fnw256 (5pp) is available online at http://dx.doi.org/10.1093/femsle/fnw256en
dc.subjectPhage therapyen
dc.subjectAIECen
dc.subjectUTIen
dc.subjectSTEAECen
dc.titlePhage therapy targeting Escherichia coli - a story with no end?en
dc.typeArticle (peer-reviewed)en
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
1749.pdf
Size:
195.92 KB
Format:
Adobe Portable Document Format
Description:
Accepted Version
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Microbiology - Journal Articles
APC Microbiome Ireland - Journal Articles